What 2020 could bring for the stock market

2019 was a heck of a year for US stocks, but can the market keep soaring in 2020?

News: What you need to know about the markets     What 2020 could bring for the stock market 2019 was a heck of a year for US stocks, but can the market keep soaring in 2020? Read more »   Stocks ended the decade with a bang Only hours of trading are left in 2019. Although stock futures are in the red Tuesday morning, the major US equity indexes are poised to finish off the year -- and the decade -- on a high note. Read more »   Carlos Ghosn's signature auto alliance has struggled since his arrest The alliance between three automakers created by Carlos Ghosn, the former auto industry bigwig who just fled Japan in advance of a scheduled trial, had a rough year after his arrest at the end of 2018. Read more »   What we don't know about Carlos Ghosn's dramatic escape from Japan Former Nissan and Renault chief Carlos Ghosn has fled Japan, where he was awaiting trial on alleged financial crimes. His destination: Lebanon. Read more »   Ex-Nissan chief Carlos Ghosn has fled Japan for Lebanon Carlos Ghosn has arrived in Lebanon after fleeing Japan, where he faced charges of financial wrongdoing, in a dramatic escape from what the former auto industry boss called a "rigged" justice system. Read more »   Cannabis industry growing pains lead MedMen to ditch Arizona MedMen Enterprises is continuing to slim down following an acquisition binge and industry downturn that left the cannabis retailer's finances in the red. Read more »

Dow Nasdaq S&P +76.30   +26.61   +9.49 28,538.44   8,972.60   3,230.78 +0.27%   +0.30%   +0.29% YTD +22.34%   YTD +35.23%   YTD +28.88%

Biggest Winners Mylan NV +3.45%   Dupont De Nemours Inc +3.07%   Mosaic Co +2.90%   DXC Technology Co +2.76% Biggest Losers NORTHROP GRUMMAN CORP -1.46%   L3Harris Technologies Inc -1.10%   Anthem Inc -1.07%   Harley-Davidson Inc -0.96%

Hottest ETF NYSE Market Volume

Key Market Stats Latest Today's Change Oil $61.21 +0.15 / +0.25% Gold $1,520.30 -2.80 / -0.18% 10-yr 1.92% +0.02 Euro $1.12 +0.00 / +0.07%

Hi, let us know what you think of this newsletter!   Tell us what you want to read more of... and less of. Email your tips and feedback to MarketsNowFeedback@turner.com

Sign up for Reliable Sources newsletter   Sign up for Before the Bell newsletter

Tips, thoughts or questions are always welcome at MarketsNowFeedback@turner.com   ® © 2016 Cable News Network Inc. A WarnerMedia Company. All Rights Reserved. You are receiving this message because you subscribed to CNN Business's "Markets Now" newsletter. Our Mailing address is: Cable News Network, Inc. Attention: Privacy Policy Coordinator One CNN Center, 13 North Atlanta, GA 30303

                                                 

This email was sent to adsbimasakti.bhinnekanews@blogger.com why did I get this?    unsubscribe from this list    update subscription preferences Cable News Network, Inc. · Attention: Privacy Policy Coordinator · One CNN Center, 13 North · Atlanta, GA 30303 · USA

Reuters Health Report: China approves home-grown vaccines, offering alternative to global drugmakers' products

Visit Reuters.com for the latest news

Reuters Health Report Your Daily Briefing       Tweet       Share China approves home-grown vaccines, offering alternative to global drugmakers' products China has approved a pneumonia vaccine developed by Chinese drugmaker Walvax Biotechnology's unit, its National Medical Products Administration said in a notice on Tuesday, offering an alternative to one of Pfizer's best-selling products Prevnar 13. Chinese officials investigate cause of pneumonia outbreak in Wuhan Chinese health authorities said they are investigating 27 cases of viral pneumonia in the central city of Wuhan, after rumors on social media suggested the outbreak could be linked to Severe Acute Respiratory Syndrome (SARS). California pharmacies rarely take back unused opioids (Reuters Health) - Only 1 in 10 California pharmacies have programs to take back unused prescription opioids and just one in five give consumers accurate disposal information, according to a study that suggests drugstores could do more to help combat substance abuse. Syrian med students trade translation services for e-learning access (Reuters Health) - Arabic-speaking medical students in war-torn Syria are providing translation services to an online educational company in exchange for free access to videos that teach clinical processes and procedures. Low levels of environmental pollutants may slow fetal growth (Reuters Health) - Pollutants that persist for decades in the environment may affect fetal growth, a U.S. study suggests. Diet Dr Pepper does not promise weight loss or deceive consumers: U.S. appeals court A U.S. federal appeals court on Monday said the maker of Diet Dr Pepper did not deceive consumers into thinking the soft drink promoted weight loss by including "diet" in its name, a decision that could doom a similar lawsuit over Diet Coke. Eye injuries from laundry pods rising in U.S. (Reuters Health) - A growing number of kids are getting chemicals from laundry detergent pods in their eyes, even as ocular injuries from other types of household cleaners steadily decline, a U.S. study suggests. Chinese court sentences 'gene-editing' scientist to three years in prison A Chinese court sentenced the scientist who created the world's first "gene-edited" babies to three years in prison on Monday for illegally practising medicine and violating research regulations, the official Xinhua news agency said. Sol-Gel acne cream reduces marks in late-stage studies, shares soar Sol-Gel Technologies Ltd's shares more than tripled in value on Monday after the company said its lead acne drug candidate, Twyneo, met the main goal of reducing marks in two late-stage studies. China bans imports of pigs from Indonesia due to African swine fever China's customs said it has banned imports of pigs, wild boars and related products from Indonesia due to African swine fever. AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer AstraZeneca and Merck's ovarian cancer drug Lynparza has received U.S. regulatory approval for the treatment of advanced pancreatic cancer, cementing its lead in a niche category of cancer treatments. Related Videos Introducing the all-new Reuters News app The new Reuters News app is here, redesigned from the ground up to fit your busy life. Get it now on iOS Your world. Your news. More Newsletters Get Reuters News App Get Reuters TV App               © 2019 Thomson Reuters. All rights reserved. 3 Times Square, New York, NY 10036 Email Preferences    |   Privacy Policy    |   Terms and Conditions